** Shares of drugmaker Axsome Therapeutics AXSM.O rise 5.9% to $108.98 premarket
** Company reports Q2 revenue of $150 mln, higher than analysts' estimate of $138.8 mln, according to data compiled by LSEG
** Says sales of its depression drug Auvelity were $119.6 mln in Q2, up 84% from $65 mln a year ago
** Reports Q2 net loss per share of 97 cents, less than loss of $1.67 per share a year earlier
** Up to last close, stock up 21.8% YTD
(Reporting by Sneha S K)
((Sneha.SK@thomsonreuters.com;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。